<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 357 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page356.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=357">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 357 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 357</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=357"><img src="../thumb/357.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>320 / 2020-04                                                                 Cytostatics - 23
   BERTRED 3,5, Dr Reddy’s [P/S]  Indications: First line treatm.in advanc./ovarian Ca second line   pancreas adenocarcinoma prev.treat.with 5-FU, transit.cell bladd. Ca,
   Bortezomib                   if other treatm.have fail., limit.evid.for small lung Ca & Ca of   unresect./loc.recurr./metastat.breast Ca combin.with paclitaxel in
   Indications: Prim.treatm.of multipl.myeloma in combinat. with   head & neck.  pts.who have relaps. follow. adjuv./neo-adjuv.ther.where prior chem-
   melphalan & prednisone, monother. for multiple myeloma where   (S4) SOL FOR INJ. Z/26/0261, 0262, A39/26/0170. 10 mg/ml.  other. incl.an anthracycl.unless C/I, alone/in combinat.for recurr.epi-
   at least one prior ther.receiv.& dis.progress., relaps./ refract.mantle   825069-010: 1x15 ml vial, R305,77  thel.ovar.Ca pts.who have relaps. follow.platin.-based chemother.
   cell lymphoma where at least one prior line ther.recd.one of which   704097-001: 1x45 ml vial, R917,55  (S4) POWD.FOR SOL.FOR INFUS. 42/26/0089, 0902
   should have incl.an anthracycl./mitoxantrone and/or rituximab  707364-001: 1X60 ml, vial, R1 223,42  715322-001: 200 mg, 1x10 ml vial, R328,33
   (S4) LYOPHIL.POWD.FOR SOL.FOR INJ, 51/26/0714. 3,5 mg/vial.  For further details refer to manufact.prod.lit.  715323-001: 1 g, 1x50 ml vial, R1 641,63
   1 mg/ml IVI reconstit.or 2,5 mg/ml SC reconstit  CIPLA DOCETAXEL, Cipla Medpro [P/S]  For further details refer to manufact.product lit.
   3000842-001: 3,5 mg/vial, 1x10 ml vial, R4 945,00.
   For further details refer to manufact.prod.lit.  Docetaxel trihydr.equiv.to docetaxel anhydr.  CYTOSAR, Pfizer [P/S]
                                                              Cytarabine.
                                Indications: Adjuvant treatm of pts with oper node-posit.breast
   BIOLYSE PACLITAXEL, Key Oncologics [P/S]   Ca.in combin.with doxorubicin & cyclophosphamide., loc.advanc./  Indications: Induct.& maint.of remiss.in ac.non-lymphocytic leu-
   Paclitaxel                   metastat.breast Ca in combinat.with doxorubicin in pts.who have   kaem.in adults & childr., ac. lymphocytic. leukaem.& chron.mye-
   Indications: Metastat.breast Ca aft.stand.ther./ combinat.chem-  not receiv.cytotox.ther.for this condit., loc.advanc./ metastat.breast   locyt.leukaem. treatm.
   other.fail./relapse within 6 mnths. of adjuv.chemother., palliat.  Ca aft.fail.of cytotox.ther., loc. advanc./ metastat.breast Ca in combi-  (S4) INJ. H2757, T/26/47.
   treatm.of advanc.non-small cell lung Ca in pts.not suit.for for curat.  nat.with capecitabine aft.fail.of cytotox.chemother.where prev.ther.  717207-005: 100 mg & dil., 1, R169,63
   surg. and/or radiat.         not incl.an anthracycline, in combinat. with cisplatin for unresect.  717215-008: 500 mg & dil., 1, R551,76
   (S4) INJ, 36/26/0024. 6 mg/ml  loc.advanc./metastat. non-small cell lung Ca when chemother.not   For further details refer to manufact.prod.lit.
   703386-001: 1x5 ml sngl.dos.vial, R398,24  prev. admin.for this condit., loc.advanc./metast.non-small cell lung   DACIN, KeyOncologics [P/S]
   For further details refer to manufact.prod.lit.  Ca even aft.fail.of platinum-bas. chemother., metastat.ovarian Ca.aft.  Dacarbazine
                                fail.of 1st line/subseq.ther., androg.independ.metast. prostate Ca in
   BUSILVEX, Pierre Fabre [P/S]  combinat.with prednisone/ prednisolone, in combinat.with cispla-  Indications: Metastat.malign.melanoma, metastat. sarcoma in
   Busulfan.                    tin & 5-fluorouracil for induct.treatm of pts.with inoper. loc. advanc.  combinat.with other chemotherapeut. meds, Hodgkin’s dis., in com-
   Indications: Condit.treatm.in adults prior to haematopoeiet.pro-  squamous cell Ca.of the head & neck.  binat. with other cytotox.agents to be of value in colon Ca/ovar.-/
   genit.cell transplantat.when cyclophosphamide & busulfan combi-  (S4) SOL.FOR INFUS, 41/26/0162, 0163   breast-/lung- & testicul. teratoma.
   nat.consid. best avail.option.  715749-001: 20 mg, 1x 5 ml vial, R903,12  (S4) LYOPHIL.POWD.FOR IV INJ, 47/26/0837
   (S4) CONC.FOR SOL FOR INJ, 37/26/0668  715807-001: 80 mg, 1x15 ml vial, R3 612,46  715877-001: 200 mg, 1 vial, R764,25
   705472-001: 6 mg/ml(aft.dilut.0,5 mg/ml), 8x10 ml vials, R33 093,98  For further details refer to manufact.prod.lit.  For further details refer to product info.
   For further details refer to prof.info.                    DACOGEN, Janssen [P/S]
                                CIPLA DOXORUBICIN, Cipla Medpro [P/S]
   CABITAS, Accord [P/S]        Doxorubicin HCl               Decitabine
   Cabazitaxel                  Indications: Ac.leukaem., metastat. adenocarcinoma of breast,   Indications: New.diagn.de novo/second.ac. myeloid leukaem.
   Indications: In combinat.with prednisone/ prednisolone for hor-  bladd.Ca, neuroblastoma, bronchogen.Ca, metastat.thyroid Ca, Ca   (AML) accord.to WHO class.in adults &gt;65 yrs.
   mone refractory metastatic prostate Ca prev.treat.with a docetaxel   of head & neck/endometrium/cervix/ prostate/testes & plasma   (S4) POWD.FOR.CONC.FOR SOL.FOR INFUS., 46/26/0608.
   contain. regimen.            cell myeloma, ovar.Ca against which it’s act.when admin.with cis-  722974-001: 50 mg, 1x20 ml sngl.dos.vial, R16 763,74
   (S4) INJ, 51/26/0326.325. 20 mg/ml  plat.& cyclophosphamide, breast Ca and small (oat) cell lung Ca   For further details refer to manufact.product lit.
   3000147-001: 1x6 ml vial, R20 287,79  with other concom.cytotox.meds., wide range sarcomas incl.Ew-  DAUNOBLASTIN, Pfizer [P/S]
   For further details refer to manufacturers product lit.  ings/osteogen.& soft tiss. sarcoma, Hodgkin’s dis.where effect.in   Daunorubicin HCl.
                                ABVD (doxorubicin/bleomycin/vinblastine & dacarbazine) combi-  Indications: Ac.myeloblast.& lymphoblast. leukaem.
   CAELYX, Janssen Pharmaceutica [P/S]  nat., non-Hodgkins lymphomas admin. concurr.in BACOP combinat.
   Doxorubicin HCl.             (S4) POWD.FOR SOL.FOR INJ, 41/26/0034, 0035  (S4) INJ. V/26/239.
                                                              717738-019: 20 mg, 1, R571,01
   Indications: As monother.in metastat.breast Ca, advanc.ovar.Ca   718301-001: 10 mg, 1x15 ml vial, R80,63
   unrespons. to first-line platinum-based chemother., in combinat.with   718302-001: 50 mg, 1x50 ml vial, R403,14  For further details refer to manufact.prod.lit.
   bortezomib for progress. multiple myeloma in pts.who have recd.   For futher details refer to manufact.prod.lit.  DOCETAXEL ACCORD, Accord [P/S]
   one prior ther & have undergone/unsuit.for bone marr.transplant,   Docetaxel anhydr.
   AIDS-related Kaposi’s sarcoma where low CD 4 counts & extens.  CIPLA IRINOTECAN, Cipla Medpro [P/S]  Indications: Breast Ca: In combinat.with doxorubicin & cyclophos-
   mucocutan./ viscer. dis.pres.  Irinotecan HCl trihydrate.  phamide, indic.for adjuv. ther.for oper.node-pos.breast Ca, combin.
   (S4) INJ. 32/26/0533. 2 mg/ml  Indications: Advanc.colorect.Ca with WHO perform.status of 2   with doxorubicin for loc.advanc.or metastat.breast Ca in pts. who
   867411-007: 1x 10 ml vial, R8 189,08  or low.in combinat.with 5-fluorouracil and folinic acid without prior   have not prev.receiv.cytotox.ther.for this condit., as monother.for loc.
   For further details refer to manufac.prod.lit.  chemother.for advanc.dis.or as sngl.agent when est. 5-fluorouracil   advanc.or metastat. breast Ca aft.fail.of cytotox.ther., in combin.with
                                contain.regim.has fail.       capecitabine for loc.advanc.or metastat.breast Ca aft. fail.of cytotox.
   CAMPTO, Pfizer [P/S]         (S4) SOL.FOR INFUS. 41/26/0049, 0050. 20 mg/ml.  ther.where prev.ther.should have incl.an anthracycline.
   Irinotecan HCl trihydrate.   716182-001: 40 mg/2 ml vial, R414,52  Non small-cell lung Ca: In combinat.with cisplatin for unresect.
   Indications: Advanc.colorect.Ca with WHO perform. status of 2   716183-001: 100 mg/5 ml vial, R1 036,30  loc.advanc./metastat.non-small cell lung Ca when chemother.not
   or low.in combinat.with 5-fluorouracil and folinic acid without prior   For further info.refer to professional info  prev. admin. for this condit., loc.advanc./metast.non-small cell lung
   chemother. for advanc.dis. or as sngl.agent when est. 5-fluoroura-  Ca even aft.fail.of platinum-bas. chemother.
   cil contain.regim.has fail.  CIPLA PACLITAXEL, Cipla Medpro [P/S]  Ovar.Ca: Metastat.ovarian Ca.aft.fail.of 1st line /subseq.chemother.
                                Paclitaxel.
   (S4) SOL.FOR INFUS. 31/26/0183. 20 mg/ml.                  Prostate Ca: In combin.with prednisone/ prednisolone for horm.
   829579-001: 100 mg sngl.dos.vial, R3 539,99  Indications: Palliat.treatm.of stage 3/4 advanc. loc.ovar.Ca aft.  refract.metastat.prostate Ca
                                surg.resect.in combinat.with cisplatin, palliat.managem.of metastat.
   For further info.refer to manuf.product lit.  ovar.Ca aft.fail.of first line/subseq.chemother., metastat. breast Ca   Head & neck Ca: In combin.with cisplatin & 5-fluorouracil for
   CAPECITABINE SPECPHARM, Specpharm [P/S]  aft.combinat.chemother.fail./relapse within 6 mnths of adjuvant   induct. reatm.of pts.with inoper. local.advanc. squamous cell Ca
   Capecitabine                 chemother.(prev. chemother.should have incl.an anthracycline un-  of the head & neck
   Indications: Loc.advanc./metastat.breast Ca: Combinat. ther.  less clinic.C/I), palliat.treatm.of advanc.non-small cell lung Ca when   (S4) CONC.FOR SOL.FOR INFUS, 49/26/0832, 0833, 0834
   with docetaxel aft.fail of cytotox. ther.incl.an anthracycline. Mono-  curat.surg.and/or radiat.not applic.  723381-001: 20 mg, 1 ml sngl.dos.vial, R755,65
   ther.aft.fail.of taxanes and an anthracycline contain.regim./ where   (S4) CONC.SOL FOR INFUS. 41/26/0423, 0424, 0425  723387-001: 80 mg, 4 ml sngl.dos.vial, R3 022,27
   anthracycline ther.not further indicat.  716178-001: 30 mg, 1x5 ml vial, R135,38  723388-001: 160 mg, 8 ml sngl.dos.vial, R6 044,53
   Colorect.Ca: Adjuv.aft.surg.in Dukes C colon Ca., metastat.colo-  716179-001: 100 mg, 1x20  ml vial, R452,22  For further details refer to manufact.prod.lit.
   rect.adenocarcinoma (benef.relates to time to progress.while over-  716180-001: 300 mg, 1x50 ml vial, R1 353,90  DOCETERE RTU, Winthrop [P/S]
   all surviv.not influenc.)    For further details refer to manufact.prod.lit.  Docetaxel trihydr.equiv.to docetaxel anhydr.
   Gastric Ca: 1  line treatm.of advanc.gastric adenocarcinoma in   CIPLA VINORELBINE, Cipla Medpro [P/S]  Indications: Loc.advanc./metastat.breast Ca in combinat.with
         st
   combinat.with other anti-chemotherapeut.regim.(benef.relates to   Vinorelbine tartr.  doxorubicin in pts.who have not receiv.cytotox.ther.for this condit.,
   time to progress.while overall surviv.not influenc.)  Indications: Palliat.treatm.of advanc.inoper.non-small cell lung Ca   monother. loc.advanc./metastat.breast Ca aft.fail.of cytotox.ther.,
   (S4) TABS, 49/26/1045, 1046  as a sngl.agent or in combinat. Combinat.ther.proves more effect.  loc.advanc./metastat.breast Ca in combinat.with capecitabine
   723214-001: 150 mg, 60, R473,63  than monother. Metastat.breast Ca in pts.where anthracycline 1   st  aft.fail.of cytotox. chemother. which should have incl.an anthracy-
   723225-001: 500 mg, 120, R3 214,40  line monother.has fail.or who have relaps.with.6 mnths.of anthra-  cline, in combinat.with cisplatin for unresect.loc.advanc./metastat.
   For furth.details refer to professional info.  cycline-based adjuv.therapy.  non-small cell lung Ca where chemother. not prev.admin.for this
   CAPEXA, (Accord) Ingwe Lifescience [P/S]  (S4) INJ. 42/26/0083, 0084. 10 mg/ml.  condit., loc.advanc./metast.non-small cell lung Ca even aft.fail.of
                                                              platinum-bas.chemother., metastat. ovarian Ca.aft.fail.of 1st line/
   Capecitabine                 716184-001: 10 mg, 1x2 ml sngl.dos.vial, R257,21  subseq.chemother.
   Indications: Loc.advanc./metastat.breast Ca: Combinat. ther.  716185-001: 50 mg, 1x5 ml sngl.dos.vial, R1 286,03
   with docetaxel aft.fail.of cytotox. ther. incl.an anthracycline. Mono-  For further details refer to manufac.prod.lit.  (S4) CONC.FOR SOL FOR INFUS, 44/26/0098, 0099
                                                              719389-001: 20 mg/1 ml, 1 vial, R764,78
   ther.aft.fail.of taxanes and an anthracycline contain.regim./ where   CISACOR, Accord [P/S]
   anthracycline ther.not further indicat.  Cisplatin         719390-001: 80 mg/4 ml, 1 vial, R3 059,08
                                                              For further details refer to manufact.prod.lit.
   Colorect.Ca: Adjuv.aft.surg.in Dukes C colon Ca., metastat. colo-  Indications: Advanc.non seminomat.testic.Ca in combin. ther.with
   rect.adenocarcinoma (benef.relates to time to progress.while over-  bleomycin & vinblastine, ovarian Ca partic.with doxyrubicin or cyclo-  DOXOLIP, Ranbaxy [P/S]
   all surviv.not influenc.)    phosphamide, Ca of bladder/head & neck/ endometrium/small cell   Doxorubicin HCl.
   Gastric Ca: 1  line treatm.of advanc.gastric adenocarcinoma in   lung Ca, lymphomas, some childhood neoplasms.  Indications: Monother.in metastat.breast Ca where incr.card.risk
         st
   combinat.with other anti-chemotherapeut. regim.(benef.relates to   (S4) SOL.FOR INFUS. 43/26/1019, 1021. 1 mg/ml  exists, advanc.ovar.Ca where 1 st  line platinum-bas.chemother.regim.
   time to progress. while overall surviv.not influenc.)  720381-001: 10 mg, 1x10 ml, R27,91  fail., AIDS-relat.Kaposi’s sarcoma with low CD4 counts & extens.
   (S4) TABS, 49/26/0683, 0684  720382-001: 50 mg, 1x50 ml, R139,56  mucocutan./visceral dis.
   722783-001: 150 mg, 60, R468,73  For further details refer to manufact.prod.lit.  (S4) CONC.FOR INFUS, 43/26/0018 2 mg/ml
   722784-001: 500 mg 120, R3 209,27                          719985-001: 20 mg/10 ml, 10 vials, R5 694,35
   For further details refer to manufact.prod.lit.  CYTIGEM, Eurolab [P/S]  For further details refer to manufac.prod.lit.
                                Gemcitabine HCl.
   CARBOSIN, (Cipla Medpro) Teva [P/S]  Indications: Loc.advanc./metastat.non-small cell lung Ca, 1st line   DOXOPEG, Key Oncologics [P/S]
   Carboplatin.                 treatm.in loc.advanc.(non-resect. stage II or III) or metast.(stage IV)   Doxorubicin HCl.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page356.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page352.html">352</a>&nbsp;&nbsp;&nbsp;<a href="page353.html">353</a>&nbsp;&nbsp;&nbsp;<a href="page354.html">354</a>&nbsp;&nbsp;&nbsp;<a href="page355.html">355</a>&nbsp;&nbsp;&nbsp;<a href="page356.html">356</a>&nbsp;&nbsp;&nbsp;<a href="page357.html">357</a>&nbsp;&nbsp;&nbsp;<a href="page358.html">358</a>&nbsp;&nbsp;&nbsp;<a href="page359.html">359</a>&nbsp;&nbsp;&nbsp;<a href="page360.html">360</a>&nbsp;&nbsp;&nbsp;<a href="page361.html">361</a>&nbsp;&nbsp;&nbsp;<a href="page362.html">362</a>
             </td>
             <td width="35%"><a href="page358.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page358.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
